Ronald Swerdloff
Endocrinology, Diabetes & Metabolism · Torrance, CANPI 1104935253
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Chiasma, Inc. at 52.5% of the total. Reporting peaked in 2021 at $7,695 and has fallen 99.4% since, to $43 in 2022.
Across 34 payments — averaging $407.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiasma, Inc.$7K
- Clarus Therapeutics Inc.$6K
- Merck$425
- Lilly USA, LLC$72
- Corcept Therapeutics$59
- AstraZeneca$56
- plus $154 from 5 others
Across 94 payments — averaging $6783.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$328K
- AbbVie$272K
- Chugai Pharmaceutical Co., Ltd.$35K
- Ascendis Pharma Endocrinology Inc$2K
- Corcept Therapeutics$1K
What the payments were for
- Consulting fees$6,42546%
- Speaking & faculty fees$4,00029%
- Travel & lodging$2,53618%
- Food & beverage$8386%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiasma, Inc. | 5 | $7,270 |
| Clarus Therapeutics Inc. | 10 | $5,814 |
| Merck | 1 | $425 |
| Lilly USA, LLC | 5 | $72 |
| Corcept Therapeutics | 4 | $59 |
| AstraZeneca | 2 | $56 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Pfizer | 2 | $36 |
| Novo Nordisk | 1 | $32 |
| Abbott | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,850 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone | 21 | $9,509 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Torrance
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.